Organogenesis Holdings Inc.
ORGONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ORGO. That does not mean none is planned.
Get an email about ORGO's next catalysts
Track Organogenesis Holdings (ORGO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Amniotic Suspension Allograft | Phase 3 | Knee Osteoarthritis | - | - |
Frequently asked questions
What is in Organogenesis Holdings Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Organogenesis Holdings Inc.'s (ORGO) pipeline across Phase 3. Its lead program is Amniotic Suspension Allograft (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Organogenesis Holdings Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Organogenesis Holdings Inc. (ORGO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ORGO biotech catalysts?→
Add ORGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Organogenesis Holdings Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.